Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of BTX-A-HAC NG for Glabellar Lines
NCT02493946Phase 3Completed
- Sponsor
- Ipsen
- Start
- Apr 2015
- Primary completion
- Oct 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of alluzience in glabellar lines, sponsored by Ipsen. Started Apr 2015; status: completed.
02
Drugs
alluzience
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT02493946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02493946.